JP2008546672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008546672A5 JP2008546672A5 JP2008516350A JP2008516350A JP2008546672A5 JP 2008546672 A5 JP2008546672 A5 JP 2008546672A5 JP 2008516350 A JP2008516350 A JP 2008516350A JP 2008516350 A JP2008516350 A JP 2008516350A JP 2008546672 A5 JP2008546672 A5 JP 2008546672A5
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- pharmaceutical composition
- sequence encoding
- family cytokine
- pegylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000006992 Interferon-alpha Human genes 0.000 claims description 25
- 108010047761 Interferon-alpha Proteins 0.000 claims description 25
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 25
- 102000004127 Cytokines Human genes 0.000 claims description 17
- 108090000695 Cytokines Proteins 0.000 claims description 17
- 108090001005 Interleukin-6 Proteins 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 102100039948 Interferon alpha-5 Human genes 0.000 claims 6
- 101710127457 Interferon alpha-5 Proteins 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 102100028892 Cardiotrophin-1 Human genes 0.000 claims 3
- 208000005176 Hepatitis C Diseases 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 108090000630 Oncostatin M Proteins 0.000 claims 3
- 102000004140 Oncostatin M Human genes 0.000 claims 3
- 108010041776 cardiotrophin 1 Proteins 0.000 claims 3
- 229940079322 interferon Drugs 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 239000012876 carrier material Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200501468 | 2005-06-16 | ||
| ES200501468A ES2302402B1 (es) | 2005-06-16 | 2005-06-16 | Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. |
| PCT/ES2006/000353 WO2006134195A2 (es) | 2005-06-16 | 2006-06-16 | Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008546672A JP2008546672A (ja) | 2008-12-25 |
| JP2008546672A5 true JP2008546672A5 (https=) | 2012-11-29 |
| JP5154412B2 JP5154412B2 (ja) | 2013-02-27 |
Family
ID=37532659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008516350A Expired - Fee Related JP5154412B2 (ja) | 2005-06-16 | 2006-06-16 | インターフェロンアルファとの組み合わせ投与のための組成物の調製における、インターロイキン６ファミリーサイトカインの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7829077B2 (https=) |
| EP (1) | EP1905447A4 (https=) |
| JP (1) | JP5154412B2 (https=) |
| CN (1) | CN101257918B (https=) |
| AU (1) | AU2006258966B8 (https=) |
| BR (1) | BRPI0611988A2 (https=) |
| CA (1) | CA2612282C (https=) |
| ES (1) | ES2302402B1 (https=) |
| MX (1) | MX2007016060A (https=) |
| RU (1) | RU2413529C2 (https=) |
| WO (1) | WO2006134195A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009762A1 (en) * | 2008-07-23 | 2010-01-28 | United Technologies Ut Ag | Interferon and an agent inducing inhibition of protein phosphatase 2a such as interleukin- 1 and optionally ribavirin for the treatment of hbv or hcv infection |
| JP2010059081A (ja) * | 2008-09-02 | 2010-03-18 | Okayama Univ | オンコスタチンｍを含有する抗ｈｃｖ剤およびその利用 |
| ES2342529B1 (es) * | 2008-10-07 | 2011-05-11 | Proyecto De Biomedicina Cima, S.L. | Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas. |
| US20120308517A1 (en) * | 2010-02-09 | 2012-12-06 | Digna Biotech, S.L. | Compositions for the treatment of infectious and tumoural diseases |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2018178215A1 (en) | 2017-03-31 | 2018-10-04 | Accanis Biotech F&E Gmbh & Co Kg | Prevention and treatment of non-melanoma skin cancer (nmsc) |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN113197910B (zh) * | 2021-05-14 | 2022-09-23 | 苏州大学 | 一种基于阿司匹林及其代谢产物提高干扰素抗病毒活性的抗病毒药盒 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284237B1 (en) | 1986-07-08 | 2001-09-04 | Steven C. Clark | Methods of treatment using IL-6 |
| IE67035B1 (en) * | 1986-07-08 | 1996-02-21 | Genetics Inst | Production and use of non-glycosylated IL-6 |
| US6348191B1 (en) | 1986-07-08 | 2002-02-19 | Genetics Institute, Inc. | Production and use of IL-6 |
| US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| PT858343E (pt) * | 1995-11-02 | 2004-07-30 | Schering Corp | Terapia por infusao continua de uma dose baixa de citoquina |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| GB9609932D0 (en) | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
| EP2298900A1 (en) * | 1996-09-17 | 2011-03-23 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating intracellular diseases |
| TW589189B (en) * | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| WO2000037096A2 (en) * | 1998-12-22 | 2000-06-29 | Schering Corporation | Treatment of hepatitis c virus infections with interleukin-10 |
| ES2200646B1 (es) * | 2001-09-21 | 2005-05-01 | Fundacion Para La Investigacion Medica Aplicada | Uso de la cardiotrofina en enfermedades hepaticas. |
| TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| RU2222345C2 (ru) * | 2002-01-21 | 2004-01-27 | Волчек Игорь Анатольевич | Фармацевтическая композиция цитокинового и иммуномодулирующего действия |
| US20050027110A1 (en) * | 2003-07-24 | 2005-02-03 | Michael Russell | Drug delivery in the nervous system |
-
2005
- 2005-06-16 ES ES200501468A patent/ES2302402B1/es not_active Expired - Fee Related
-
2006
- 2006-06-16 CN CN2006800299002A patent/CN101257918B/zh not_active Expired - Fee Related
- 2006-06-16 BR BRPI0611988-3A patent/BRPI0611988A2/pt not_active IP Right Cessation
- 2006-06-16 CA CA2612282A patent/CA2612282C/en not_active Expired - Fee Related
- 2006-06-16 AU AU2006258966A patent/AU2006258966B8/en not_active Ceased
- 2006-06-16 WO PCT/ES2006/000353 patent/WO2006134195A2/es not_active Ceased
- 2006-06-16 EP EP06794028A patent/EP1905447A4/en not_active Withdrawn
- 2006-06-16 JP JP2008516350A patent/JP5154412B2/ja not_active Expired - Fee Related
- 2006-06-16 RU RU2008100307/15A patent/RU2413529C2/ru not_active IP Right Cessation
- 2006-06-16 MX MX2007016060A patent/MX2007016060A/es active IP Right Grant
- 2006-06-16 US US11/922,221 patent/US7829077B2/en not_active Expired - Fee Related
-
2010
- 2010-09-22 US US12/887,843 patent/US20110027224A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | Interferons: Success in anti-viral immunotherapy | |
| Gao et al. | STAT proteins–key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver | |
| Perry et al. | Peginterferon-α-2a (40kD) A review of its use in the management of chronic hepatitis C | |
| JP2008546672A5 (https=) | ||
| Isorce et al. | Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies | |
| JP2008513356A5 (https=) | ||
| CA2573207A1 (en) | Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv) | |
| US20110027224A1 (en) | Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha | |
| CN1764475A (zh) | 治疗病毒性疾病和肝纤维化的干扰素药物治疗 | |
| EP2739301A1 (en) | Hcv immunotherapy | |
| EP2292652A2 (en) | Interferons uses and compositions related thereto | |
| EP2535057A2 (en) | Compositions for the treatment of infectious and tumoural diseases | |
| Nishimura et al. | Acute onset of nephrotic syndrome during interferon-α retreatment for chronic active hepatitis C | |
| McHutchison et al. | Future trends in managing hepatitis C | |
| CA2627531A1 (en) | Interferon-alpha and c-phycocyanin for the treatment of autoimmune diseases, allergic diseases and cancer | |
| Brown Jr et al. | 41 Differences in treatment outcome to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the Win-R trial | |
| Tan et al. | Gene cloning, sequencing, expression and biological activity of giant panda (Ailuropoda melanoleuca) interferon-α | |
| Clark et al. | Novel interferons for treatment of hepatitis C virus | |
| Witthoeft et al. | [655] PEG-IFN ALFA-2a PLUS RIBAVIRIN IS SUPERIOR COMPARED TO HIGH DOSE CONSENSUS INTERFERON (CIFN) AND RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C | |
| Dev et al. | Current standard of care in hepatitis C virus infection | |
| RU2401268C2 (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА (R)-6-ЦИКЛОПЕНТИЛ-6-(2-(2,6-ДИЭТИЛПИРИДИН-4-ИЛ)ЭТИЛ)-3-((5,7-ДИМЕТИЛ-[1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-2-ИЛ)МЕТИЛ)-4-ГИДРОКСИ-5,6-ДИГИДРОПИРАН-2-ОНА, ЕЕ ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕЕ | |
| Blum | Locally Produced Peginterferon As An Opportunity to Treat HCV in Low and Mid-Income Countries | |
| Piguet et al. | 42 The mitochondrial AMP-lysine hydrolase, HINT2, sensitizes experimental hepatocellular carcinoma to FAS-induced apoptosis | |
| Tacke | LETTER TO | |
| Zehnter et al. | [656] THE ROLE OF GLOMERULAR FILTRATION RATE (GFR) FOR TREATMENT WITH PEGINTERFERON ALFA 2a (PEG) AND RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) |